Reconstructing functional networks in the human intestinal tract þÿusing synthetic microbiomes : Systems Biology '

Shetty, Sudarshan A

2019-08

Shetty , S A , Smidt , H & de Vos , W M 2019 , ' Reconstructing functional networks in the þÿhuman intestinal tract using synthetic microbiomes : Systems Biology ' , Current Opinion in Biotechnology , vol. 58 , pp. 146-154 . https://doi.org/10.1016/j.copbio.2019.03.009

http://hdl.handle.net/10138/304577
https://doi.org/10.1016/j.copbio.2019.03.009

Available online at www.sciencedirect.com

ScienceDirect

Current Opinion in Biotechnology

Reconstructing functional networks in the human intestinal tract using synthetic microbiomes

Sudarshan A Shetty[1], Hauke Smidt[1] and Willem M de Vos[1,2]

The human intestinal tract harbors one of the most densely populated and open microbial ecosystems. The application of multi-omics approaches has provided insight into a wide array of complex interactions between the various groups of mainly anaerobic colonic microbes as well as the host–microbe dialogue. Integration of multi-omics techniques in cultivation based experiments that vary in complexity from monocultures to synthetic microbial communities identified key metabolic players in the trophic interactions as well as their ecological dynamics. A synergy between these approaches will be of utmost importance to reconstruct the functional interaction networks at the ecosystem level within the human intestinal microbiome. The improved understanding of microbiome functioning at ecosystem level will further aid in developing better predictive models and design of effective microbiome modulation strategies for health benefits.

Addresses
[1] Laboratory of Microbiology, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands
[2] Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Corresponding author: Smidt, Hauke (hauke.smidt@wur.nl)

Current Opinion in Biotechnology 2019, **58**:146–154

This review comes from a themed issue on **Systems biology**

Edited by **Maria Klapa** and **Yannis Androulakis**

https://doi.org/10.1016/j.copbio.2019.03.009

Introduction

The microbes in the colon are in a continuous state of dynamic interactions with the host as well as other microbes. Consequently, microbes play a major role in balancing human health while the human host also has an impact on the survival of microbes [1–3]. The trophic interactions in the intestinal tract facilitate co-existence of complementary species that share the resources derived from consumed food and products generated by the host [4•]. Studying the metabolic interactions as well as identifying emergent biosynthetic pathways resulting from multiple interacting species is challenging due to the complexity of the intestinal microbiome that includes over 1000 species of mainly anaerobic bacteria, archaea, and fungi [5].

The colon is the most densely populated site in the human intestinal tract, and an anaerobic fermentative lifestyle is the major physiological characteristic of the high numbers of bacteria and archaea that reside there. These convert the substrates originating from host-associated glycans or dietary fibers and proteins that have not been taken up by the host. Fermentation end products such as short-chain fatty acids (SCFAs), including acetate, propionate and butyrate, as well as medium chain fatty acids (MCFAs), like caproate, and branched chain fatty acids (BCFAs), such as iso-butyrate and isovalerate, play a crucial role in normal host physiology [1,6–9]. This central metabolism in the colon results in a thriving ecosystem giving rise to highly complex and dynamic interactions between the microbes themselves and between the host and microbes. Consequently, diet is considered as a promising avenue for modulating the microbiome for achieving health benefits by supporting the growth of known beneficial microbes [10,11]. However, our understanding of the complex metabolic interactions resulting from different dietary fibers is limited. Finally, understanding the ecological principles governing the assembly, structure, and function of the microbiome under the influence of diet and consequent metabolic interactions have not been studied in detail. Therefore, integrating the ecological information obtained through population level microbiome studies and the physiological information obtained through *in-vitro* and *in-vivo* studies is vital for reconstructing the functional interaction networks at the community level to design better microbiome modulation strategies.

Reconstructing functional networks using fecal samples

It is important to acknowledge that intestinal microorganisms are not independently growing free-living entities. Information obtained from investigation of a given bacterium in isolation may not represent its natural lifestyle. Therefore, it will be crucial to study bacterial populations as communities by growing multiple bacterial species together in well-controlled settings that mimic the natural ecosystem. Integration of multi-disciplinary approaches will be crucial for improving our knowledge regarding the physiology, interaction networks and role of intestinal microorganisms in human health (Figure 1).

Figure 1



Synergistic approach to understanding individual to ecosystem level microbial interactions and their impact on the host.

Fecal samples have been widely used in batch and continuous fermentation systems to investigate the fate of dietary fibers and resulting microbial interaction networks. Resistant carbohydrates, which include resistant starch, non-starch polysaccharides (NSP) and oligosaccharides (including pre-biotics, e.g. fructo-ologosaccharides, galacto-oligosaccharides), are important determinants of microbial composition and function [6,10,12,13]. Mucus-derived glycans are another important growth and energy source, and their utilization has major implications for host health as mucus acts as a barrier against pathogen invasion [14•,15,16]. Most of our understanding of the microbial metabolic interactions has been derived from investigating faecal samples by metagenomic and to some extent by metatranscriptomic and metaproteomic approaches. These have been used for both *in-vivo* and *in-vitro* anaerobic fermentation systems. Inoculation of *in vitro* anaerobic fermentation systems containing different carbohydrates has revealed a predominance of *Bacteroides* species [17]. Several *Bacteroides* species are capable of utilizing diverse carbohydrates and thus are considered to be one of the most metabolically versatile groups in the human intestinal tract. Dietary interventions in humans and subsequent molecular analysis of fecal samples have revealed phylotypes related to *Ruminococcaceae* as dominant groups in resistant starch utilization, whereas phylotypes related to *Lachnospiraceae* were dominant in NSP degradation [18]. A recent dietary intervention study investigating the effect of resistant starch 2 (RS2) in human subjects included metagenomics and observed that *Ruminococcus bromii* contributed the majority of the key genes for RS2 degradation, further validating its role as a key degrader of resistant starch [19•,20]. A major challenge in reconstructing microbial interaction networks using fecal samples is the presence of a large number of unknown functions that have not been annotated well. In natural samples, the unknown contribution of bacteriophages, and the high variability across different inocula pose major challenges in deciphering the microbial interactions. Moreover, the role of uncultured microorganisms in governing ecological outcomes *via* hitherto unknown interactions makes predictive modelling a challenging activity. Finally, most currently employed sequencing-based molecular

techniques are incapable of species/strain level identification and annotation with high confidence, while the design and application of qPCR primers to allow discrimination at strain or species level is often technically challenging and expensive [21,22]. Strain-level resolution can be obtained from shotgun metagenome sequencing data, albeit limited to the top 0.1% of the microbes in the total community and at a higher cost [23,24]. For a better understanding of complex systems, such as the human intestinal microbiome, a pragmatic approach would be to study the ecosystem in parts under well-controlled conditions. Studying defined microbial communities could provide a promising avenue where major properties such as known species composition and their genetic potential (sequenced genome), as well as known general physiological characteristics can be leveraged to better understand the metabolic roles and interaction networks and to develop predictive models for the microbiome.

Reconstructing functional networks using cultured microorganisms from the human intestinal tract

Specialist bacteria capable of degrading complex dietary fibers and mucus are key players in the community as they provide simple carbohydrates for other microbes in the community. Known examples of such bacteria are *R. bromii*, *Eubacterium rectale* and *Bacteroides thetaiotaomicron* capable of degrading complex polysaccharides, and *Akkermansia muciniphila*, *Barnesiella intestinihominis* and *Bacteroides caccae* that are capable of degrading mucus [20,25,26••,27,28]. An experimentally verified metabolic interaction network is the one between *A. muciniphila* and butyrate producers *Anaerostipes caccae, Eubacterium hallii,* and *Faecalibacterium prausnitzii* [14•]. The butyrate producers benefitted from simple sugars released from mucus by *A. muciniphila*, and in return *A. muciniphila* benefitted from the *E. hallii*-mediated production of vitamin B12, an important co-factor in the propionate biosynthesis pathway.

In-vitro growth assays have identified polysaccharide-degrading bacteria that utilize the dietary carbohydrates reaching the colon undigested. For example, resistant starch can be utilized by *R. bromii* and *E. rectale*, xylan can be utilized by *Bacteroides intestinalis*, *Bacteroides ovatus*, *Bacteroides dorei*, *Bacteroides cellulosilyticus*, *Bacteroides xylanisolvens* and *Roseburia intestinalis*, whereas pectin can be used by *B. ovatus*, *B. thetaiotaomicron*, some strains of *F. prausnitzii*, *Eubacterium eligens* and *Lachnospira pectinoschiza* [6,20,29–31]. Co-culture experiments combining degraders and non-degraders have revealed interesting cross-feeding pathways, such as utilization of lactate to produce butyrate or propionate [32]. This has allowed reconstructing the dominant metabolic pathway starting from degradation of dietary carbohydrates to production of dominant SCFAs detected in feces *viz.* acetate, butyrate, and propionate. Formate and lactate are known intermediates of microbial fermentation but are detected in low amounts in feces. Conversion of formate produced by amylolytic bacteria (*R. bromii*) to acetate by an acetogen (*Blautia hydrogenotrophica*) has been recently shown to be a contributing factor for high amounts of acetate [33]. Potential emergent properties that are related to biosynthetic pathways for amino acid, vitamin and co-factor metabolism and other non-central metabolic pathways have been identified using RNA-sequencing in both *in-vivo* and *in-vitro* co-culture experiments [33–37]. However, the influence of regulation of secondary biosynthesis pathways in the presence of interacting partners and subsequent impact on the overall community level functional interaction network is largely unknown. Therefore, there is a need to incorporate high complexity in terms of phylogenetic and functional diversity in experiments aimed at reconstructing the functional interaction network in the human intestinal tract.

Leveraging the concept of minimal microbiomes for reconstructing functional networks of the human intestinal microbiome

One approach to better understand the microbial interaction networks and develop predictive modelling tools is to grow microorganisms in combinations as co-, tri- or even more complex cultures, building up to create a consortium of microorganisms that could be representative of a functioning minimal microbial community of the human intestinal tract. The first attempt at developing a defined microbial community in a host was done in 1965 by Russell W. Schaedler *et al.*, who composed the 'Schaedler flora' comprising five dominant bacterial isolates in mice [38]. The 'Schaedler flora' was further modified to include three more isolates. This Altered Schaedler flora (ASF) has been widely used to study the relationship between the murine host and intestinal microbiota [39,40]. A proof of concept study showed the applicability of the ASF in therapeutically modulating the murine host metabolism as to decrease intestinal ammonia levels as the eight bacteria that make up the ASF have a minimal urease gene content [41••].

A number of other defined microbial communities have been designed to investigate microbial interactions, develop predictive models and study specific hypotheses such as conferring colonization resistance (CR) against pathogens in a host (Table 1). The complexity of these defined microbial communities ranges from 2 to 33 bacterial isolates while the selection is often based on characteristics such as dominance and prevalence. These defined microbial communities can be considered as a minimal microbiome, a term coined previously to describe the smallest set of microbes and/or microbial functions needed to develop a stable community [42]. These minimal microbiomes allow researchers to gain mechanistic insights regarding several aspects of host-microbiome and within microbiome interactions [26••,43••,44,45]. The recently developed Minimal

Table 1

Defined intestinal microbial communities and their application. This summary only lists those that include three or more strains

Original host of bacterial isolates	Defined intestinal microbial communities	No. of isolates	Selection approach	Application(s)	Ref (s)
Human	Microbial Ecosystem Therapeutic (MET)	33	Cultivation of bacteria from donor feces. Screened for antibiotic resistance. Susceptible isolates chosen representing *Bacteroidetes*, *Firmicutes*, *Actinobacteria* and *Proteobacteria*.	Proposed alternative to fecal transplant by repopulating the intestinal tract with defined bacterial communities representative of the normal microbiota.	[52••]
	Synthetic Gut Community (SGC-1)	3	Isolated from human feces, abundant with genome sequence available. *Faecalibacterium prausnitzii* and *Roseburia intestinalis* were chosen for ability to produce butyrate, while *Blautia hydrogenotrophica* was chosen for its ability to utilize CO_2 and H_2 apart from its ability to produce acetate. All belong to *Firmicutes*.	A minimal model to investigate interactions between the intestinal bacteria as well to develop predictive models for community dynamics.	[50••]
	Synthetic Human Gut Microbiome Communities	12	Isolated from human feces and chosen to cover major functions and phylogenetic diversity present in the human intestinal tract. The community has representatives from phyla *Bacteroidetes*, *Firmicutes*, *Actinobacteria*, and *Proteobacteria*.	Useful for developing predictive models for microbial community dynamics as well as investigate microbial interactions involved in community assembly.	[51••]
	Model 15-member human gut microbiota	15	Isolated from human feces, representatives from phyla *Bacteroidetes*, *Firmicutes*, and *Actinobacteria*.	Used for investigating the spatial organization of the key intestinal tract bacteria at different scales.	[53]
	Synthetic Microbiota (SM)	14	Genome sequenced human intestinal isolates representing the five dominant phyla *Bacteroidetes*, *Firmicutes*, *Actinobacteria*, *Verrucomicrobia*, and *Proteobacteria* and ability to carry out important core metabolic functions such as mucus and dietary fiber degradation as well as short chain fatty acid production.	Effect of dietary fiber deprivation was investigated along with its effect on mucus layer.	[26••]
Mice	Oligo-Mouse-Microbiota (Oligo-MM^{12}) plus Facultative anaerobes (FA^3)	15	Bacterial isolates cultivated from the specified pathogen-free (SPF) mice. Isolates representative of most prevalent and abundant phyla *Bacteroidetes*, *Firmicutes*, *Actinobacteria*, *Verrucomicrobia*, and *Proteobacteria*.	The Oligo-MM^{12} was tested for its ability to confer colonization resistance against *Salmonella enterica* serovar *Typhimurium*. Incorporating three isolates of FA^3 provided colonization resistance similar to the conventional complex mice microbiota	[43••]
	Schaedler flora (SF)	5	Dominant bacteria isolated from mice. Aerobic and aerotolerant anaerobic bacteria	Initially used to create gnotobiotic mouse.	[38]
	Altered Schaedler flora (ASF) [39,54••,55]	8	Modified version which included ASF356 (*Clostridium* sp.), ASF360 (*Lactobacillus intestinalis*), ASF361 (*Lactobacillus murinus*), ASF457 (*Mucispirillum schaedleri*), ASF492 (*Eubacterium plexicaudatum*), ASF500 (*Pseudoflavonifractor* sp.), ASF502 (*Clostridium* sp.) and ASF519 (*Parabacteroides goldsteinii*)	Widely used for investigating mechanisms host-microbiota relationship as well as microbe–microbe interactions.	
	Altered Schaedler flora (ASF), Shen *et al.*, 2015	7 out of 8 original strains	*Parabacteroides goldsteinii* (ASF519) ASF356 (*Clostridium* sp.), ASF361 (*Lactobacillus murinus*), ASF457 (*Mucispirillum schaedleri*), ASF492 (*Eubacterium plexicaudatum*), ASF500 (*Pseudoflavonifractor* sp.), ASF502 (*Clostridium* sp.). Missing strain was ASF360	Original ASF strains were maintained in was laboratory mice. Proportional abundances varied in the host and had minimal urease activity. This ASF was demonstrated to treat hyperammonemiain mice model	[41••]
Minimal	Bacteriome (MIBAC-1)	18	*Bacteroidetes*, *Firmicutes*, *Verrucomicrobia*, *Proteobacteria*, *Actinobacteria* representative of strains enriched in mouse.	Update to the Altered Schaedler flora. Highly representative of mouse gut microbiome and can be used for studying microbe–microbe and host–microbe interactions	[46••]

Bacteriome (MIBAC-1) consisting of 18 mouse derived bacterial strains is an example of one such a minimal microbiome and may replace the ASF in future studies of the mouse microbiome. From the extensive culture collection of mouse intestinal microorganisms, a minimal bacterial consortium (Oligo-MM^{12}) was designed to investigate CR against *Salmonella enterica* serovar *Typhimurium* [43••,46••]. *In-vivo* experiments with Oligo-MM^{12} revealed the importance of facultative anaerobes in improving CR. These two studies demonstrated the importance of combining large scale culturing approaches and multi-omics to investigate mechanisms of host–microbe interactions.

When designing a minimal microbiome, it is important to consider the major factors influencing the intestinal microbiome. For example, diet is a major source of carbon and energy and other nutrients required for growth for intestinal bacteria, alongside host-derived compounds such as mucus. Diet, especially components that cannot be digested by the host, influence the composition and metabolic (fermentation) activity of the microbiome [2,18,47]. For instance breakdown of starch and fructo-oligosaccharides results in cross-feeding not only *via* the partial breakdown products of complex substrates but also due to the fermentation end products (lactate and acetate) produced by primary degraders and consumed by butyrate-producing bacteria [48]. High functional redundancy, especially with regards to the butyrate producers using monosaccharides leads to competition for resources in the intestinal microbiome [49]. Recently, two studies used synthetic communities to model community dynamics and metabolic interactions between dominant and prevalent human intestinal bacteria [50••,51••]. Investigation of pair-wise interactions and community dynamics of a consortium of 12 human intestinal bacterial strains was used to build predictive models of community assembly and co-existence [51••]. Using a combination of mathematical modelling, culturing, metabolite measurements, and transcriptomics of a three species synthetic community, an emergent metabolic behavior was identified in *F. prausnitzii*, which downregulated the B12 production pathway due to its availability from partners in the tri-culture [50••]. The design of the three species synthetic community incorporated both potential cross-feeding as well as competitive interactions thereby allowing the investigation and predictive modelling of metabolic interactions driving such ecological interactions [50••].

Conceptual understanding for the design of minimal microbiomes

Complex ecological processes determine the successful assembly of microbial communities, and thermodynamic constraints, metabolic pathways, and regulatory circuits play a major role in successful survival and propagation at the level of individual microbial cells [56,57]. Therefore, integrating these features in top-down and bottom-up approaches for the design of minimal microbiomes is essential. The latter approach would involve understanding the metabolic roles played by each of the bacteria identified in the human intestinal microbiome. The size and complexity of a minimal microbiome can be tuned to address two main broadly defined aims, that is, 1) unravelling metabolic interactions, 2) investigating key ecological concepts. For example, lactate and acetate are produced as a result of fermentation and breakdown of polysaccharides by bacteria such as *E. rectale*, *R. bromii* or *Bifidobacterium* spp. and they can be subsequently used by *E. hallii* and related species to produce butyrate [58,59•]. Two-species systems have been used in order to understand trophic metabolic interactions addressing polysaccharide degradation and butyrate production [60,61•]. Similarly, trophic metabolic interactions between mucus degraders and butyrate producers have been studied using two-species systems [14•]. The two-species systems can be upgraded to incorporate ecosystem processes of competition, by including two competing polysaccharide degraders, and two butyrate producers that compete for polysaccharide breakdown products. Such four-species cultures can be used to investigate pairwise species competition and complementarity as well as metabolic inter-dependencies. To address specific ecological concepts, the design should aim at higher complexity to more comprehensively mimic the human intestinal microbiome. For example, to investigate the effect of functional redundancy on community assembly, selection of bacterial species that have functional overlap at different trophic levels will be crucial. Ecophysiology guided approaches that incorporate the knowledge of physiology, metabolic potential of each species with their ecological roles, and properties such as prevalence, dominance and rarity will be important in the rational design of minimal microbiomes that mimic natural ecosystems.

Challenges, opportunities, and future prospects

Several bacteria remain uncharacterized

There exists a major lacuna in our understanding of the metabolic roles of individual species, especially of some core species such as *Subdoligranulum variable*, *Coprococcus eutactus*, *Lachnospira pectinoschiza* and members of *Dialister* and *Collinsella*, to just name a few. In addition to these, bacteria related to the genus *Oscillibacter*, uncharacterized *Lachnospiraceae* and uncharacterized *Ruminococcoceae* have been cultured and sequenced as part of the human microbiome project, MetaHIT reference genomes, Culturable Genome Reference (CGR) and Human Gastrointestinal Bacteria Culture Collection (HBC) and are consistently identified in molecular profiling studies of the microbiome [62–65]. However, due to a lack of metabolic characterization, their roles in the community remain elusive. In addition to the cultured bacterial species, there remain a few key bacterial groups that

have not yet been grown as pure cultures, one example being *Oscillospira* and related bacteria [66,67]. While high-throughput cultivation strategies, also termed culturomics, have achieved success in cultivating a claimed >70% of the human intestinal bacteria, isolation of some key species will require more targeted approaches [68]. These approaches will require integrating the knowledge of their ecology and predicted nutrient requirements based on metagenome-assembled genomes.

Using *in-silico* approaches to model and predict microbial community level interactions and dynamics has received considerable interest [69–71,72••]. However, a major challenge with the currently available bioinformatics tools is the accuracy of functional annotations for genomes and metagenomes. Improvements in the accuracy of genome annotation tools will be crucial for metabolic modelling approaches that are used to simulate and predict microbial interactions in defined as well as natural communities. Recently, a large number of semi-curated constraint-based metabolic models of human intestinal bacteria were created [73•]. These models are now being used to investigate microbial interactions in communities as well as in pairs of microorganisms [74•]. A graph theory-based approach employing metabolic networks to identify species complementarity and competition is also available [75]. Results and observation of both constraint-based metabolic models and graph theory-based metabolic networks are only as good as the functional gene annotation that the current bioinformatics tools provide. A major challenge is to annotate transporter genes, which encode key functions that influence the accuracy of *in-silico* prediction of microbial interactions [73•,76]. By integrating multi-omics data and physiological studies, metabolic models have been developed for *A. muciniphila* (iAkkMuc_588), *F. prausnitzii* (*iFpraus_v1.0*), *Bacteroides thetaiotamicron* (iBth1201), *Eubacterium rectale* (iEre400), and the methanogen *Methanobrevibacter smithii* (iMsi385) [77–79]. Focus on developing improved metabolic models for these and other core microorganisms will be crucial for improving the accuracy of our understanding of the metabolic interaction networks and predictive modelling, involving the designing of minimal microbiomes with known ecophysiological properties.

Minimal microbiome(s) to understand the intricacies of the intestinal microbiome

Minimal microbiomes will be crucial for unravelling active metabolic networks and potential interactions which may be hidden due to the extensive technical noise and several unknowns in the studies based on natural communities (for e.g. feces). Minimal microbiomes allow for studying emergent metabolic behaviors that could explain the evolution of co-operation and competition between the microbial members [26••,45,50••,51••]. There still remains a wide-open field for similar studies investigating several combinations of core and non-core species to address diverse research questions. Multi-species interactions, which incorporate competition for mucus or dietary fiber breakdown products and other nutrients, and potential emergent properties of these interactions have not been investigated. Importantly, the effect of diet and mucus degrading key stone species on the overall community dynamics remains understudied. We propose that future development of minimal microbiomes should address these questions by designing-specific minimal microbiomes. For instance, to investigate the ecological and metabolic interaction dynamics in the mucus layer, a mucus-based minimal microbiome which could include mucin degraders and other co-occurring bacteria can be designed.

The understanding of ecophysiological features of natural microbiomes using minimal microbiomes can have far reaching implications in the design and development of therapeutics. More than two decades ago, a mixture of ten different facultative aerobic and anaerobic bacterial strains was shown to inhibit *Clostridioides difficile* in five patients suffering from chronic relapsing diarrhoea [80••]. Years later, a defined consortium of 33 bacterial strains (MET-1) has shown potential in treatment of *C. difficile* infections [52••]. However, the mechanism of action of these live therapeutics is unknown. Therefore, investigation of host–microbe interaction dynamics will be crucial for unravelling the mechanism of action of such minimal microbiomes. Development of predictive models for *in-situ* behavior of minimal microbiomes will be necessary for achieving effective therapeutic success in humans. Designing minimal microbiomes with defined functional outputs, such as the production of butyrate, sequestering of ammonia, or synthesis of vitamin B12, holds a promise for targeted intervention strategies. In addition to these live microbial therapeutics, cell-free supernatants with bioactive metabolites can be produced in industrial scale fermenters using minimal microbiomes to mimic the natural extracellular components in the human intestinal tract.

Conclusions/outlook

The last few years have seen a rise in studies that move forward from mere associations to identifying mechanisms of how microbes influence host health. One of the major focus areas has been the understanding of metabolic interactions and ecological dynamics. Moving forward from co-cultures and tri-cultures, the studies employing minimal microbiomes are expected to provide insights that are relevant at the ecosystem level. Synergy between culture independent and dependent experimental approaches driven by specific hypotheses is expected to play a crucial role in advancing our knowledge of microbial communities associated with human and animal hosts and for developing effective microbiome modulation strategies.

Conflict of interest statement

Nothing declared.

Acknowledgements

This work was supported by the Soehngen Institute for Anaerobic Microbiology024-002-002 grant to WMdV and the UNLOCK project (NRGWI.obrug.2018.005) of the Netherlands Organisation for Scientific Research (NWO) to HS.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- • of special interest
- •• of outstanding interest

1. Flint HJ, Scott KP, Louis P, Duncan SH: **The role of the gut microbiota in nutrition and health**. *Nat Rev Gastroenterol Hepatol* 2012, **9**:577.

2. Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL: **Diet-induced extinctions in the gut microbiota compound over generations**. *Nature* 2016, **529**:212.

3. de Vos WM, de Vos EA: **Role of the intestinal microbiome in health and disease: from correlation to causation**. *Nutr Rev* 2012, **70**:S45-S56.

4. • Kovatcheva-Datchary P, Egert M, Maathuis A, Rajilić-Stojanović M, De Graaf AA, Smidt H, De Vos WM, Venema K: **Linking phylogenetic identities of bacteria to starch fermentation in an in vitro model of the large intestine by RNA-based stable isotope probing**. *Environ Microbiol* 2009, **11**:914-926.

This work elegantly describes the active microbial members involved in starch fermentation using RNA-based stable isotope probing.

5. Rajilić-Stojanović M, de Vos WM: **The first 1000 cultured species of the human gastrointestinal microbiota**. *FEMS Microbiol Rev* 2014, **38**:996-1047.

6. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E: **Microbial degradation of complex carbohydrates in the gut**. *Gut Microbes* 2012, **3**:289-306.

7. Davie JR: **Inhibition of histone deacetylase activity by butyrate**. *J Nutr* 2003, **133**:2485S-2493S.

8. Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, Bultman SJ: **The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon**. *Cell Metab* 2011, **13**:517-526.

9. Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G: **Butyrate and propionate protect against diet-induced obesity and regulate gut hormones *via* free fatty acid receptor 3-independent mechanisms**. *PLoS One* 2012, **7**:e35240.

10. Chung WSF, Walker AW, Louis P, Parkhill J, Vermeiren J, Bosscher D, Duncan SH, Flint HJ: **Modulation of the human gut microbiota by dietary fibres occurs at the species level**. *BMC Biol* 2016, **14**:3.

11. Gibson GR: **Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin**. *J Nutr* 1999, **129**:1438S-1441S.

12. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA: **Diet rapidly and reproducibly alters the human gut microbiome**. *Nature* 2014, **505**:559-563.

13. Salonen A, de Vos WM: **Impact of diet on human intestinal microbiota and health**. *Ann Rev Food Sci Technol* 2014, **5**:239-262.

14. • Belzer C, Chia LW, Aalvink S, Chamlagain B, Piironen V, Knol J, de Vos WM: **Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B12 production by intestinal symbionts**. *mBio* 2017, **8**:e00770-00717.

On the basis of known co-occurrence relationships from molecular surveys, this study reconstructs the functional interactions between key mucus degraders and butyrate producers.

15. Belzer C, de Vos WM: **Microbes inside—from diversity to function: the case of *Akkermansia***. *ISME J* 2012, **6**:1449-1458.

16. Derrien M, Belzer C, de Vos WM: ***Akkermansia muciniphila* and its role in regulating host functions**. *Microb Pathog* 2017, **106**:171-181.

17. Duncan SH, Scott KP, Ramsay AG, Harmsen HJ, Welling GW, Stewart CS, Flint HJ: **Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system**. *Appl Environ Microbiol* 2003, **69**:1136-1142.

18. Salonen A, Lahti L, Salojärvi J, Holtrop G, Korpela K, Duncan SH, Date P, Farquharson F, Johnstone AM, Lobley GE: **Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men**. *ISME J* 2014, **8**:2218-2230.

19. • Vital M, Howe A, Bergeron N, Krauss RM, Jansson JK, Tiedje JM: **Metagenomic insights into resistant starch degradation by human gut microbiota**. *Appl Environ Microbiol* 2018, **84** e01562-18.

Using multi-omics approach, this study describes the key role of *R. bromii* in resistant starch degradation and the subsequent cross-feeding by butyrate producers as well as H2 scavenging bacteria.

20. Ze X, Duncan SH, Louis P, Flint HJ: ***Ruminococcus bromii* is a keystone species for the degradation of resistant starch in the human colon**. *ISME J* 2012, **6**:1535-1543.

21. Ramiro-Garcia J, Hermes GD, Giatsis C, Sipkema D, Zoetendal EG, Schaap PJ, Smidt H: **NG-Tax, a highly accurate and validated pipeline for analysis of 16S rRNA amplicons from complex biomes**. *F1000Research* 2016, **5**.

22. Edgar RC: **Accuracy of microbial community diversity estimated by closed-and open-reference OTUs**. *PeerJ* 2017, **5**:e3889.

23. Scholz M, Ward DV, Pasolli E, Tolio T, Zolfo M, Asnicar F, Truong DT, Tett A, Morrow AL, Segata N: **Strain-level microbial epidemiology and population genomics from shotgun metagenomics**. *Nat Methods* 2016, **13**:435.

24. Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY: **Durable coexistence of donor and recipient strains after fecal microbiota transplantation**. *Science* 2016, **352**:586-589.

25. Derrien M, Vaughan EE, Plugge CM, de Vos WM: ***Akkermansia muciniphila* gen. nov., sp. nov., a human intestinal mucin-degrading bacterium**. *Int J Syst Evol Microbiol* 2004, **54**:1469-1476.

26. •• Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A: **A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility**. *Cell* 2016, **167**:1339-1353 e1321.

This study uses a human derive minimal microbial community to study the effect of dietary fiber deprivation on the host health using a mouse model. A good example of application of defined microbial community to study host–microbe interactions.

27. Ravcheev DA, Godzik A, Osterman AL, Rodionov DA: **Polysaccharides utilization in human gut bacterium *Bacteroides thetaiotaomicron*: comparative genomics reconstruction of metabolic and regulatory networks**. *BMC Genomics* 2013, **14**:873.

28. Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI: **A genomic view of the human-*Bacteroides thetaiotaomicron* symbiosis**. *Science* 2003, **299**:2074-2076.

29. Chassard C, Delmas E, Lawson PA, Bernalier-Donadille A: ***Bacteroides xylanisolvens* sp. nov., a xylan-degrading bacterium isolated from human faeces**. *Int J Syst Evol Microbiol* 2008, **58**:1008-1013.

30. Chassard C, Goumy V, Leclerc M, Del'homme C, Bernalier-Donadille A: **Characterization of the xylan-degrading microbial**

community from human faeces. *FEMS Microbiol Ecol* 2007, **61**:121-131.

31. Salyers A, Vercellotti J, West S, Wilkins T: **Fermentation of mucin and plant polysaccharides by strains of *Bacteroides* from the human colon**. *Appl Environ Microbiol* 1977, **33**:319-322.

32. Louis P, Flint HJ: **Formation of propionate and butyrate by the human colonic microbiota**. *Environ Microbiol* 2017, **19**:29-41.

33. Laverde Gomez JA, Mukhopadhya I, Duncan SH, Louis P, Shaw S, Collie-Duguid E, Crost E, Juge N, Flint HJ: **Formate cross-feeding and cooperative metabolic interactions revealed by transcriptomics in co-cultures of acetogenic and amylolytic human colonic bacteria**. *Environ Microbiol* 2018, **21**:259-271.

34. Chia LW, Hornung BV, Aalvink S, Schaap PJ, de Vos WM, Knol J, Belzer C: **Deciphering the trophic interaction between *Akkermansia muciniphila* and the butyrogenic gut commensal *Anaerostipes caccae* using a metatranscriptomic approach**. *Antonie van Leeuwenhoek* 2018:1-15.

35. Crost EH, Le Gall G, Laverde-Gomez JA, Mukhopadhya I, Flint HJ, Juge N: **Mechanistic insights into the cross-feeding of *Ruminococcus gnavus* and *Ruminococcus bromii* on host and dietary carbohydrates**. *Front Microbiol* 2018, **9**.

36. Rey FE, Faith JJ, Bain J, Muehlbauer MJ, Stevens RD, Newgard CB, Gordon JI: **Dissecting the *in vivo* metabolic potential of two human gut acetogens**. *J Biol Chem* 2010, **285**:22082-22090.

37. Sonnenburg JL, Chen CT, Gordon JI: **Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host**. *PLoS Biol* 2006, **4**:e413.

38. Schaedler RW, Dubos R, Costello R: **Association of germfree mice with bacteria isolated from normal mice**. *J Exp Med* 1965, **122**:77-82.

39. Orcutt R, Gianni F, Judge R: **Development of an "Altered Schaedler Flora" for NCI gnotobiotic rodents**. *Microecol Ther* 1987, **17**.

40. Wymore Brand M, Wannemuehler MJ, Phillips GJ, Proctor A, Overstreet A-M, Jergens AE, Orcutt RP, Fox JG: **The altered Schaedler flora: continued applications of a defined murine microbial community**. *ILAR J* 2015, **56**:169-178.

41. •• Shen T-CD, Albenberg L, Bittinger K, Chehoud C, Chen Y-Y, Judge CA, Chau L, Ni J, Sheng M, Lin A: **Engineering the gut microbiota to treat hyperammonemia**. *J Clin Invest* 2015, **125**:2841-2850.
A proof of concept study which demonstrated the applicability of defined bacterial consortia to treat hyperammonemia in mice.

42. de Vos WM: **Fame and future of faecal transplantations–developing next-generation therapies with synthetic microbiomes**. *Microb Biotechnol* 2013, **6**:316-325.

43. •• Brugiroux S, Beutler M, Pfann C, Garzetti D, Ruscheweyh H-J, Ring D, Diehl M, Herp S, Lötscher Y, Hussain S: **Genome-guided design of a defined mouse microbiota that confers colonization resistance against *Salmonella enterica* serovar *Typhimurium***. *Nat Microbiol* 2017, **2**:16215.
This study elegantly demonstrates the design of a mice minimal microbiome that confers colonization resistance comparable to that of a conventional mice microbiota. It also shows the importance of facultative anaerobes in the intestinal tract as their inclusion was vital for improved colonization resistance.

44. Stecher B, Robbiani R, Walker AW, Westendorf AM, Barthel M, Kremer M, Chaffron S, Macpherson AJ, Buer J, Parkhill J: ***Salmonella enterica* serovar *typhimurium* exploits inflammation to compete with the intestinal microbiota**. *PLoS Biol* 2007, **5**:e244.

45. Clavel T, Lagkouvardos I, Stecher B: **From complex gut communities to minimal microbiomes *via* cultivation**. *Curr Opin Microbiol* 2017, **38**:148-155.

46. •• Lagkouvardos I, Pukall R, Abt B, Foesel BU, Meier-Kolthoff JP, Kumar N, Bresciani A, Martínez I, Just S, Ziegler C: **The Mouse Intestinal Bacterial Collection (miBC) provides host-specific insight into cultured diversity and functional potential of the gut microbiota**. *Nat Microbiol* 2016, **1**:16131.
An extensive collection of microbes isolated from mice which may be used to replace Altered Schaedler Flora. Reports a wide array of growth conditions for capturing large bacterial diversity in culture. Additionally, one minimal consortia of mice-enriched bacterial strains are designed.

47. Voreades N, Kozil A, Weir TL: **Diet and the development of the human intestinal microbiome**. *Front Microbiol* 2014, **5**:494.

48. Belenguer A, Duncan SH, Calder AG, Holtrop G, Louis P, Lobley GE, Flint HJ: **Two routes of metabolic cross-feeding between *Bifidobacterium adolescentis* and butyrate-producing anaerobes from the human gut**. *Appl Environ Microbiol* 2006, **72**:3593-3599.

49. Coyte KZ, Schluter J, Foster KR: **The ecology of the microbiome: networks, competition, and stability**. *Science* 2015, **350**:663-666.

50. •• D'hoe K, Vet S, Faust K, Moens F, Falony G, Gonze D, Lloréns-Rico V, Gelens L, Danckaert J, De Vuyst L: **Integrated culturing, modeling and transcriptomics uncovers complex interactions and emergent behavior in a three-species synthetic gut community**. *eLife* 2018, **7**:e37090.
The authors used a simplified three-species bacterial community and tested the influence of partners on growth. The authors developed a mathematical model which could predict the tri-culture community dynamics using data obtained from bi-culture growth experiments. Integration of transcriptomics allowed the authors for identifying emergent behavior in *F. prausnitzii* which downregulated the B12 production pathway due to it availability from partners in tri-culture.

51. •• Venturelli OS, Carr AV, Fisher G, Hsu RH, Lau R, Bowen BP, Hromada S, Northen T, Arkin AP: **Deciphering microbial interactions in synthetic human gut microbiome communities**. *Mol Syst Biol* 2018, **14**:e8157.
Using a defined microbial community of 12 species, the authors decipher microbial interactions and build predictive models which demonstrate the importance of pairwise interactions as drivers of multi-species community dynamics.

52. •• Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E: **Stool substitute transplant therapy for the eradication of *Clostridium difficile* infection: 'RePOOPulating' the gut**. *Microbiome* 2013, **1**:3.
This study elegantly demonstrates the potential for using defined bacterial communities as alternative to fecal microbiota transplant in curing antibiotic-resistant *Clostridium difficile* infection.

53. Welch JLM, Hasegawa Y, McNulty NP, Gordon JI, Borisy GG: **Spatial organization of a model 15-member human gut microbiota established in gnotobiotic mice**. *Proc Natl Acad Sci U S A* 2017, **114**:E9105-E9114.

54. •• Medlock GL, Carey MA, McDuffie DG, Mundy MB, Giallourou N, Swann JR, Kolling GL, Papin JA: **Inferring metabolic mechanisms of interaction within a defined gut microbiota**. *Cell Syst* 2018, **7**:245-257 e247.
The authors employ a systems level approach to elucidate the metabolic interactions between the members of the altered Schaedler flora (ASF). The authors make well-designed use of *in vitro* mono-culture and co-culture growth assays, constraint based genome scale metabolic models and metabolomics to developed a Constant Yield Expectation Model. This is a promising approach for elucidating interspecies interactions and developing predictive modeling for microbial communities.

55. Biggs MB, Medlock GL, Moutinho TJ, Lees HJ, Swann JR, Kolling GL, Papin JA: **Systems-level metabolism of the altered Schaedler flora, a complete gut microbiota**. *ISME J* 2017, **11**:426.

56. Scheffer M, van Nes EH, Vergnon R: **Toward a unifying theory of biodiversity**. *Proc Natl Acad Sci U S A* 2018, **115**:639-641.

57. Brown JH, Gillooly JF, Allen AP, Savage VM, West GB: **Toward a metabolic theory of ecology**. *Ecology* 2004, **85**:1771-1789.

58. Shetty SA, Zuffa S, Bui TPN, Aalvink S, Smidt H, De Vos WM: **Reclassification of *Eubacterium hallii* as *Anaerobutyricum hallii* gen. nov., comb. nov., and description of *Anaerobutyricum soehngenii* sp. nov., a butyrate and propionate-producing bacterium from infant faeces**. *Int J Syst Evol Microbiol* 2018, **68**:3741-3746.

59. • Duncan SH, Louis P, Flint HJ: **Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product**. *Appl Environ Microbiol* 2004, **70**:5810-5817.
First study to demonstrate the role of lactate as a key cross-feeding metabolite between a starch-degrading species and butyrate producers in human intestinal tract.

60. De Vuyst L, Leroy F: **Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifdobacterial competitiveness, butyrate production, and gas production**. *Int J Food Microbiol* 2011, **149**:73-80.

61. • Scott KP, Martin JC, Duncan SH, Flint HJ: **Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro**. *FEMS Microbiol Ecol* 2014, **87**:30-40.
This study elegantly shows which of the key intestinal tract bacteria can utilize which of the common complex polysaccharide as well as the effect of chain length on the ability of bacteria to degrade these fibers.

62. Consortium HMJRS: **A catalog of reference genomes from the human microbiome**. *Science* 2010, **328**:994-999.

63. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, Arumugam M, Kultima JR, Prifti E, Nielsen T: **An integrated catalog of reference genes in the human gut microbiome**. *Nat Biotechnol* 2014, **32**:834-841.

64. Zou Y, Xue W, Luo G, Deng Z, Qin P, Guo R, Sun H, Xia Y, Liang S, Dai Y *et al.*: **1520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses**. *Nat Biotechnol* 2019, **37**:179-185.

65. Forster SC, Kumar N, Anonye BO, Almeida A, Viciani E, Stares MD, Dunn M, Tapoka TM, Zhu A, Shao Y *et al.*: **A human gut bacterial genome and culture collection for improved metagenomic analyses**. *Nat Biotechnol* 2019, **37**:186-192.

66. Gophna U, Konikoff T, Nielsen HB: ***Oscillospira* and related bacteria–from metagenomic species to metabolic features**. *Environ Microbiol* 2017, **19**:835-841.

67. Konikoff T, Gophna U: ***Oscillospira*: a central, enigmatic component of the human gut microbiota**. *Trends Microbiol* 2016, **24**:523-524.

68. Lagier J-C, Khelaifia S, Alou MT, Ndongo S, Dione N, Hugon P, Caputo A, Cadoret F, Traore SI, Dubourg G: **Culture of previously uncultured members of the human gut microbiota by culturomics**. *Nat Microbiol* 2016, **1**:16203.

69. De Roy K, Marzorati M, Van den Abbeele P, Van de Wiele T, Boon N: **Synthetic microbial ecosystems: an exciting tool to understand and apply microbial communities**. *Environ Microbiol* 2014, **16**:1472-1481.

70. Großkopf T, Soyer OS: **Synthetic microbial communities**. *Curr Opin Microbiol* 2014, **18**:72-77.

71. Bauer E, Thiele I: **From network analysis to functional metabolic modeling of the human gut microbiota**. *MSystems* 2018, **3**: e00209-00217.

72. •• Sung J, Kim S, Cabatbat JJT, Jang S, Jin Y-S, Jung GY, Chia N, Kim P-J: **Global metabolic interaction network of the human gut microbiota for context-specific community-scale analysis**. *Nat Commun* 2017, **8**:15393.
Creation of first systems-based community level microbe–microbe and microbe–host metabolic interaction network.

73. • Magnúsdóttir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, Greenhalgh K, Jäger C, Baginska J, Wilmes P: **Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota**. *Nat Biotechnol* 2017, **35**:81.
Largest collection of semi-curated genome scale metabolic models (GEMs). These GEMs provide a starting point for modelling metabolic interaction networks at different scale from two species to community-level.

74. • Baldini F, Heinken A, Heirendt L, Magnusdottir S, Fleming RMT, Thiele I: **The Microbiome Modeling Toolbox: from microbial interactions to personalized microbial communities**. *Bioinformatics* 2018, **1–3** bty941-bty941.
An *in-silico* toolbox for simulating pairwise microbe–microbe and host–microbe interactions using constrained-based metabolic models. This toolbox allows for integrating metagenomics data to reconstruct community level microbial interactions.

75. Levy R, Borenstein E: **Metabolic modeling of species interaction in the human microbiome elucidates community-level assembly rules**. *Proc Natl Acad Sci U S A* 2013, **110**:12804-12809.

76. Greenblum S, Chiu H-C, Levy R, Carr R, Borenstein E: **Towards a predictive systems-level model of the human microbiome: progress, challenges, and opportunities**. *Curr Opin Biotechnol* 2013, **24**:810-820.

77. Shoaie S, Karlsson F, Mardinoglu A, Nookaew I, Bordel S, Nielsen J: **Understanding the interactions between bacteria in the human gut through metabolic modeling**. *Sci Rep* 2013, **3**:2532.

78. Heinken A, Khan MT, Paglia G, Rodionov DA, Harmsen HJM, Thiele I: **Functional metabolic map of *Faecalibacterium prausnitzii*, a beneficial human gut microbe**. *J Bacteriol* 2014, **196**:3289-3302.

79. Ottman N, Davids M, Suarez-Diez M, Boeren S, Schaap PJ, dos Santos VAM, Smidt H, Belzer C, de Vos WM: **Genome-scale model and omics analysis of metabolic capacities of *Akkermansia muciniphila* reveal a preferential mucin-degrading lifestyle**. *Appl Environ Microbiol* 2017, **83**:e01014-e01017.

80. •• Tvede á, Rask-Madsen J: **Bacteriotherapy for chronic relapsing *Clostridium difficile* diarrhoea in six patients**. *Lancet* 1989, **333**:1156-1160.
Earliest report of treating chronic relapsing *Clostridium difficile* diarrhea using a defined consortia of bacterial strains.